GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Payments to Suppliers for Goods and Services

TNF Pharmaceuticals (LTS:0A8D) Payments to Suppliers for Goods and Services


View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Payments to Suppliers for Goods and Services?

Payments to Suppliers for Goods and Services only applicable to companies reporting Cash Flow from Operations in direct method.


TNF Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Payments to Suppliers for Goods and Services
Traded in Other Exchanges
Address
1185 Avenue of the Americas, Suite 249, New York, NY, USA, 10036
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.